Select a medication above to begin.
Ozempic
semaglutide
Black Box Warnings .
Thyroid C-cell Tumor Risk
contraindicated in pts w/ medullary thyroid carcinoma (MTC) hx or family hx, or in pts w/ multiple endocrine neoplasia syndrome type 2 (MEN 2); dose-related and duration-dependent incr. in thyroid C-cell tumor incidence observed in rodents, but human relevance unknown; uncertain value of routine serum calcitonin or thyroid ultrasound monitoring; advise pts of potential MTC risk and thyroid tumor sx (e.g., neck mass, dysphagia, dyspnea, persistent hoarseness)
Adult Dosing .
Dosage forms: INJ (pen): 2 mg per 3 mL, 4 mg per 3 mL, 8 mg per 3 mL
Special Note
- [prescribing info]
- Info: see other injectable semaglutide product for FDA-approved weight management dosing
- [strength clarification]
- Info: 2 mg per 3 mL pen delivers 0.25 mg or 0.5 mg per injection; 4 mg per 3 mL pen delivers 1 mg per injection; 8 mg per 3 mL pen delivers 2 mg per injection
diabetes mellitus, type 2
- [0.5-2 mg SC qwk]
- Start: 0.25 mg SC qwk x4wk, then incr. to 0.5 mg SC qwk, then may incr. to 1 mg SC qwk after at least 4wk, then may incr. to 2 mg SC qwk after at least 4wk; Max: 2 mg/wk; Info: give doses >48h apart
cardiovascular event risk reduction - DM type 2 pts w/ estab. cardiovascular dz
- [0.5-2 mg SC qwk]
- Start: 0.25 mg SC qwk x4wk, then incr. to 0.5 mg SC qwk, then may incr. to 1 mg SC qwk after at least 4wk, then may incr. to 2 mg SC qwk after at least 4wk if additional glycemic control needed; Max: 2 mg/wk; Info: give doses >48h apart
renal dosing
- [see below]
- renal impairment: no adjustment
- HD/PD: not defined
hepatic dosing
- [no adjustment]
Peds Dosing .
Peds dosing is currently unavailable or not applicable for this drug.